TECHNOLOGY SUMMARY

We engineered effective anticancer agents derived from a fungal natural product to treat chemotherapy resistance, a massive clinical and economic burden. By forcing resistant cancer cells to reduce volume, this novel mechanism overcomes treatment failure. These agents offer a safer and more effective therapeutic option for patients.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech & Medical

Technology Development Status: Prototype

Technology Readiness Level: TRL 4

Vetted Programs/Awards: We received the Formosa Innovation Award (2025) from Formosa Plastics Corporation ($17,000) and BobCatalyst Proof of Concept (POC) Grant (2025) from Texas State University ($30,000) to advance this technology toward commercialization.

SHOWCASE SUMMARY

Organization Type: R&D/Laboratory/University

Website: https://kornienkoresearchgroup.wp.txstate.edu/

MARKET KEYWORDS

Market Keywords: refractory cancer, unmet clinical need, novel mechanism of action